Fiziotens 0.4 mg Storage
active substance: moxonidine;
1 tablet contains moxonidine 0.2 mg or 0.3 mg or 0.4 mg;
excipients: lactose monohydrate; povidone K25; crospovidone; magnesium stearate; tablet shell: hypromellose, ethylcellulose aqueous dispersion 30%, macrogol 6000, talc, iron oxide red (E 172), titanium dioxide (E 171).
Fiziotens 0.4 mg Dosage form
Basic physical and chemical properties:
tablets of 0.2 mg – round convex tablets of light pink color with an imprint of “0.2” on one side;
tablets of 0.3 mg – round convex tablets of pale red color with an imprint of “0.3” on one side;
tablets of 0.4 mg – round convex tablets of matte red color with an imprint of “0.4” on one side.
Fiziotens 0.4 mg Pharmacotherapeutic group
Antihypertensive drugs. Imidazoline receptor agonists. Moxonidine. ATX code C02A C05.
Moxonidine has been shown to be an effective antihypertensive agent. Available experimental data suggest that the central nervous system (CNS) is the site of antihypertensive action of moxonidine. Moxonidine is a selective agonist of imidazoline receptors. These imidazoline-sensitive receptors are concentrated in the rostral part of the ventrolateral part of the medulla oblongata, an area thought to be the center of regulation of the peripheral sympathetic nervous system. Stimulation of imidazoline receptors reduces the activity of the sympathetic nervous system and lowers blood pressure.
Moxonidine differs from other sympatholytic antihypertensive drugs by relatively low affinity for known α2-adrenoceptors compared to imidazoline receptors. Due to this, the sedative effect and dry mouth when using moxonidine are rare.
In humans, the use of moxonidine leads to a decrease in peripheral vascular resistance with a subsequent decrease in blood pressure. The antihypertensive effect of moxonidine was demonstrated in double-blind placebo-controlled randomized trials. Published data indicate that the use of angiotensin II antagonist (AIIA) together with moxonidine in patients with hypertension and left ventricular hypertrophy with the same decrease in blood pressure allowed to achieve regression of regression of left ventricular hypertrophy and calcaneal blond compared with free.
In therapeutic studies lasting 2 months, moxonidine increased the insulin sensitivity index by 21% in patients with moderate hypertension, obesity and insulin resistance compared with placebo.
Moxonidine is contraindicated in:
hypersensitivity to the active substance or to any component of the drug;
sinus node weakness syndrome;
bradycardia (heart rate at rest below 50 beats / min);
AV-blockade of the II and III degree;
Interaction with other medicinal products and other forms of interaction
Concomitant use of the drug with other antihypertensive drugs leads to an additive effect.
Because tricyclic antidepressants may reduce the effectiveness of centrally acting antihypertensive drugs, concomitant use of these drugs with moxonidine is not recommended.
Moxonidine may potentiate the sedative effect of tricyclic antidepressants (concomitant use should be avoided), tranquilizers, alcohol, sedatives and hypnotics.
Moxonidine moderately potentiates cognitive impairment in patients receiving lorazepam. Moxonidine may potentiate the sedative effect of benzodiazepines when co-administered.
Moxonidine is excreted by tubular excretion. Interactions with other agents excreted by tubular excretion cannot be ruled out. However, studies with digoxin and hydrochlorothiazide did not reveal any evidence of interaction. The bioavailability of glibenclamide when administered orally decreased by 11%.